

<b>Notice of References Cited</b>	Application/Control No. 10/763,424		Applicant(s)/Patent Under Reexamination KARLIK ET AL.	
	Examiner Maher M. Haddad		Art Unit 1644	Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-6,284,473	09-2001	Whitaker et al.	435/7.1
*	B	US-6,753,135	06-2004	Alters et al.	435/4
*	C	US-5,840,299	11-1998	Bendig et al.	424/133.1
*	D	US-6,602,885	08-2003	Baroudy et al.	514/316
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 00/15247	03-2000	PCT	Mundy et al	-----
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Cannella et al. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis PNAS Vol. 95, Issue 17, 10100-10105, August 18, 1998.
	V	Warrington et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6820-5.
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.